Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials

By sjmartinez • October 22, 2022

Roth ME, Parsons SK, Ganz PA, Wagner LI, Hinds PS, Alexander S, Bingen K, Bober SL, Brackett J, Cella D, Henry NL, Indelicato DJ, Johnson RH, Miller TP, Rosenberg SM, Schmitz KH, Thanarajasingam G, Reeve BB, Salsman JM. Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials. J Natl Cancer Inst. 2022 Oct 21:djac166. doi: 10.1093/jnci/djac166. Epub ahead of print. PMID: 36266760.

Tags: Hematology/Oncology, Publications

Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity that Associates with a Clinically Aggressive Subtype of Prostate Cancer

Zhang L, Teng PC, Cavassani KA, Wang J, Grasso C, Watson J, Chen Z, Tu KH, Salumbides B, Rohena-Rivera K, Gevorkian L, Kim M, You[...]

Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study

McCann KE, Osman N, Cannon J, Brent L, Wang Y, Tepsick J, Mandora PV, Miller V, Martin N, Kaklamani VG. Goserelin 3-month depot shows non-inferiority[...]

A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative)

Rugo HS, Schmid P, Tolaney SM, Marmé F, Bardia A, Spears PA, Cortés J. A plain language summary of quality of life with sacituzumab govitecan[...]